Enrofloxacin Market – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Enrofloxacin (ENR) is a fluoroquinolone antibiotic and a veterinary antibacterial agent. It is sold under the trade name Baytril by the Bayer Corporation. ENR is currently approved for treatment of individual pets and domestic animals in the U.S. by the U.S. Food and Drug Administration (FDA). ENR is effective against a several gram-positive and gram-negative bacteria such as Pseudomonas aeruginosa, Klebsiella, and E.coli.

Leave a Reply

Your email address will not be published. Required fields are marked *